Prof David Isenberg

Photo

Personal Profile

Name: David Isenberg Email: d.isenberg@ucl.ac.uk
Title: Prof Tel: 0203 108 2148
Department: Inflammation Fax: 0203 108 2152
Position: ARC Diamond Jubilee Professor Address: The Rayne Building, 4th Floor, 5 University Street, London, WC1E 6JF
Research Domain: Infection, Immunology & Inflammation, Personalised Medicine Web Page:  

Profile

Research Description

With an immunlogy background ( trained in the laboratories of Ivan Roitt, London and Robert Schwartz, Boston) I developed a number of human hybridoma derived autoantibodies for detailed analysis. My colleagues and I have incorporated amino acid sequencing, computer modelling, site directed mutagenesis and experimental models to explore the links between the structure, function and pathogenic consequences of anti dsDNA and anti phospholipid autoantibodies. The Centre For Rheumatology has also developed an international reputation for its work on T and B cell interactions and regulation, cell signalling, analysis of lipid rafts and apoptosis amongst other things. Clinically I have been deeply involved in the development of the BILAG disease activity assessment tool for patients with lupus. I have also been instrumental in developing a dmaage index for patients lupus and simlar tools for patients with myositis and Sjogren's syndome. Our group was also the first to use B cell depletion as a form of treatment for patients with rheumatoid arthritis (now NICE approved) and lupus.

Research Activities

Immunoregulation in rheumatic disease

Interaction of membrane proteins and lipids on immune cell function and immune synapse formation.

Rheumatology

characterisation of the genetic and immunological

Education Description

UCL Collaborators

Prof Patricia Woo; Prof Mala Maini; Dr Sian Henson; Prof Claudia Mauri; Dr John Ioannou; Prof Stan Newman; Prof Mike Ehrenstein; Dr Liz Jury; Prof Steve Humphries; Prof Lucy Wedderburn

External Collaborators

Publications

    2011

    • Isenberg DA, Allen E, Farewell V, D'Cruz D, Alarcón GS, Aranow C, Bruce IN, Dooley MA, Fortin PR, Ginzler EM, Gladman DD, Hanly JG, Inanc M, Kalunian K, Khamashta M, Merrill JT, Nived O, Petri M, Ramsey-Goldman R, Sturfelt G, Urowitz M, Wallace DJ, Gordon C, Rahman A (2011). An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA.. Ann Rheum Dis, 70(1), 54 - 59. doi:10.1136/ard.2010.132068
    • Sultan SM, Allen E, Cooper RG, Agarwal S, Kiely P, Oddis CV, Vencovsky J, Lundberg IE, Dastmalchi M, Hanna MG, Isenberg DA (2011). Interrater reliability and aspects of validity of the myositis damage index.. Ann Rheum Dis, 70(7), 1272 - 1276. doi:10.1136/ard.2010.142117
    • Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N, ALMS Group (2011). Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.. N Engl J Med, 365(20), 1886 - 1895. doi:10.1056/NEJMoa1014460

    2010

    • Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C (2010). CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.. Immunity, 32(1), 129 - 140. doi:10.1016/j.immuni.2009.11.009

    2009

    • Manson JJ, Jury E, Mills K, Isenberg DA, Rahman A (2009). The Podocyte in Lupus Nephritis: How do Pathogenic Autoantibodies Exert Their Effect?. Rheumatology, 48, I47 - I47.
    • Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA (2009). A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.. Arthritis Rheum, 61(4), 482 - 487. doi:10.1002/art.24341
    • O Neill SG, Woldman S, Bailliard F, Norman W, McEwan J, Isenberg DA, Taylor AM, Rahman A (2009). Cardiac magnetic resonance imaging in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 68(9), 1478 - 1481.
    • Ioannou Y, Romay-Penabad Z, Pericleous C, Giles I, Papalardo E, Vargas G, Shilagard T, Latchman DS, Isenberg DA, Rahman A, Pierangeli S (2009). In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta-glycoprotein I: proof of concept. Journal of Thrombosis and Haemostasis, 7(5), 833 - 842.

    2008

    • Everett CM, Graves TD, Lad S, Jager HR, Thom M, Isenberg DA, Hanna MG (2008). Aggressive CNS lupus vasculitis in the absence of systemic disease activity. Rheumatology, 47(1), 107 - 109. doi:10.1093/rheumatology/kem264
    • McBride JD, Gabriel FG, Fordham J, Kolind T, Barcenas-Morales G, Isenberg DA, Swana M, Delves PJ, Lund T, Cree IA, Roitt IM (2008). Screening autoantibody profiles in systemic rheumatic disease with a diagnostic protein microarray using a filtration assisted Nanodot Array Luminometric ImmunoAssay (NALIA).. Clinical Chemistry, 54, 883 - 890. doi:10.1373/clinchem.2007.098418

    2007

    • Rider LG, Pilkington CM, Ruperto N, Isenberg DA (2007). Charting your child's progress. In Rider LG, Pachman LM, Miller FW, Bollar H (Ed.), Myositis and you: a guide to juvenile dermatomyositis for patients, families and healthcare providers (pp. 127 - 138). : The Myositis Association.
    • O'Neill SG, Isenberg DA, Rahman A (2007). Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?. Annals of the Rheumatic Diseases, 66, 989 - 991.
    • Giles I, Isenberg D, A (2007). Antinuclear antibodies: an overview.. In (Ed.), Dubois Lupus (pp. 415 - 424). : Lippincot and Williams.
    • Chambers SA, Rahman A, Isenberg DA (2007). Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology, 46, 895 - 898.
    • Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A (2007). 50 years of anti-dsDNA antibodies - are we approaching journey's end. Rheumatology, 46, 1052 - 1056.
    • Jury EC, Eldridge J, Isenberg DA, Kabouridis PS (2007). Agrin signalling contributes to cell activation and is overexpressed in T lymphocytes from lupus patients. The Journal of Immunology, 179(11), 7975 - 7983.
    • Bernatsky S, Ramsey-Goldman R, Isenberg DA, Rahman A, Dooley MA, Sibley J, Boivin JF, Joseph L, Armitage J, Zoma A, Clarke A (2007). Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology, 46, 830 - 832.
    • Chambers SA, Charman SC, Rahman A, Isenberg DA (2007). Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Annals of the Rheumatic Diseases, 66, 1173 - 1177.
    • Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A (2007). Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta 2-glycoprotein I: Mutation studies including residues R39 to R43. Arthritis and Rheumatism, 56(1), 280 - 290. doi:10.1002/art.22306
    • Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RAAR2007J (2007). Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus.. Arthritis and Rheumatism, 56(1), 291 - 302.
    • Lambrianides A, Giles I, Ioannou Y, Mason L, Latchman DS, Manson JJ, Isenberg DA, Rahman A (2007). Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. Arthritis and Rheumatism, 56(7), 2392 - 2401. doi:10.1002/art.22743

    2006

    • Cambridge G, Leandro M, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JCW (2006). B cell depletion therapy in systemic lupus erythematosus; effect on autoantibody and antimicrobial antibody profiles. Arthritis and Rheumatism, 54, 3612 - 3622.
    • Adler M, Isenberg D, A (2006). Working together to improve rheumatology services.. Clin Medicine, 3, 309 - 311.
    • Isenberg DA, Rahman A (2006). Systemic lupus erythematosus - 2005 annus mirabilis?. Nature Clinical Practice Rheumatology, 2, 145 - 152. doi:10.1038/ncprheum0116
    • Isenberg DA (2006). The benefits and costs of biologic registers.. Nature Clinical Practice Rheumatology, 2, 229 - 229.
    • Adler M, Chambers S, Edwards C, Neild GH, Isenberg D (2006). An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period.. Rheumatology, 45, 1144 - 1147.
    • Mason J, Isenberg DA (2006). The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus.. Exp Review of Clin Immunol, 2, 377 - 380.
    • Yee CS, Farewell V, Isenberg D, Prabu A, Sokoll K, Teh LS, Rahman A, etal (2006). Revised BILAG-2004 index: a reliable tool for assessment of SLE disease activity.. Arthritis and Rheumatism, 54, 3300 - 3305.
    • Ng KP, Manson JJ, Rahman A, Isenberg DA (2006). Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.. Arthritis Care and Research, 55(6), 900 - 904. doi:10.1002/art.22356
    • Bessant R, Duncan R, Ambler G, Swanton J, Isenberg DA, Gordon C, Rahman A (2006). Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Care and Research, 55(6), 892 - 899. doi:10.1002/art.22343
    • Giles IP, Isenberg DA, Rahman A (2006). Lessons from sequence analysis of monoclonal antiphospholipid antibodies. In Khamashta MA (Ed.), Hughes Syndrome (pp. - ). : Springer.
    • Allen E, Farewell VT, Isenberg DA, Gordon C (2006). A statistical analysis of the inter-relationships between disease activity in different systems in systemic lupus erythematosus.. Rheumatology, 45, 308 - 313.
    • Jury EC, Isenberg DA, Mauri C, Ehrenstein MR (2006). Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus.. The Journal of Immunology, 177(10), 7416 - 7422.
    • Ng K, P L, M J, Edwards J, C Ehrenstein M, R C, G I, D A (2006). Repeated B cell depletion in treatment of refactory systemic lupus erythemaosus.. Annals of the Rheumatic Diseases, 65, 942 - 945.
    • Donnelly S, Roake W, Brown S, Young P, Naik H, Wordsworth P, Isenberg DA (2006). Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus.. Arthritis and Rheumatism, 54(5), 1543 - 1556.
    • Rahman A, Bessant R, Isenberg DA (2006). What do lupus specialists believe about managing conventional cardiovascular risk factors in patients with systemic lupus erythematosus?. Lupus, 15, 695 - 697.
    • Ioannou Y, Giles I, Lambrianides A, Richardson C, Pearl LH, Latchman DS, Isenberg DA, Rahman A (2006). A novel expression system of Domain I of human Beta2 Glycoprotein I in Escherichia Coli. BMC Biotechnology, 6(1), 8 - 18.

    2005

    • Kumar S, Nagl SCB, Kalsi JK, Ravirajan CT, Athwal D, Latchman DS, Pearl LH, Isenberg DA (2005). Beta-2-glycoprotein specificity of human anti-phospholipid antibody resides on the light chain: a novel mechanism for acquisition of cross-reactivity by an autoantibody. Molecular Immunology, 42(1), 39 - 48. doi:10.1016/j.molimm.2004.07.012
    • Kumar S, Bunting KA, Kalsi J, Hinks JA, Latchman DS, Pearl LH, Isenberg DA (2005). Lupus autoantibodies to native DNA preferentially bind DNA presented on PolIV. Immunology, 114(3), 418 - 427.
    • Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D'Cruz D, Griffiths B, Khamashta M, Maddison P, McHugh N, Snaith M, Teh LS, Yee LS, Zoma A, Gordon C (2005). BILAG 2004 - Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.. Rheumatology, 44, 902 - 906.
    • Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA (2005). B cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.. Rheumatology, 44, 1542 - 1545.
    • Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, Gordon C, Barr S, Edworthy S, Petri M, Bae SC, Sibley J, Isenberg DA, Rahman A, et A (2005). Race/ethnicity and cancer occurrence in systemic lupus erythematosus.. Arthritis and Rheumatism, 53, 781 - 784.
    • Chinoy H, Salway F, Fertig N, Shepherd N, Tait BD, Thomson W, Isenberg DA, Oddis CV, Silman AJ, Ollier WE, Cooper RG (2005). The UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC): In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype rather than by myositis sub type.. Arthritis Research and Therapy, 8(1), R13 - .
    • Giles I, Lambrianides N, Latchman D, Chen P, Chukwuocha R, Isenberg D, Rahman A (2005). The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.. Arthritis Research and Therapy, 7(1), R47 - 56. doi:10.1186/ar1449
    • Swanton J, Isenberg DA (2005). Mixed connective tissue disease: still crazy after all these years.. Rheum Dis Clin N America, 31, 421 - 436.
    • Mason LJ, Lambrianides A, Haley JD, Manson JJ, Latchman DS, Isenberg DA, Rahman A (2005). Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Research and Therapy, 7(5), R971 - R983.
    • Haley J, Mason LJ, Nagl S, Giles I, Latchman DS, Isenberg DA, Rahman A (2005). Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen.. Molecular Immunology, 40(11), 745 - 758.
    • Ripley BJM, Goncalves B, Isenberg DA, Latchman DS, Rahman A (2005). Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Annals of the Rheumatic Diseases, 64(6), 849 - 853.
    • Ioannou Y, Giles I, Lambrianides N, Latchman DS, Isenberg DA, Rahman A (2005). A novel, efficient, expression system of domain I of human beta2 glycoprotein I in E-coli. RHEUMATOLOGY, 44, I141 - I142.
    • Hoffman IEA, Peene I, Cebecaver L, Isenberg DA, Huizinga TWA, Union A, Meheus L, De Bosschere K, Hulstaert F, Veys EM, De Keyser F (2005). Presemce of rheumatoid factor and antibodies to citrullinated peptides in SLE. Presence of rheumatoid factor and antibodies to citrullinated peptides in SLE.. Annals of the Rheumatic Diseases, 64, 330 - 332.
    • Panopalis P, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, Penrod JR, Joseph L, St Pierre Y, Pineau C, Fortin P, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile J, Clarke AE (2005). The systemic lupus erythematosus tri-nation study: longitudinal changes in physician and mental well-being.. Rheumatology, 44, 751 - 755.
    • Ripley BJM, Rahman A, Isenberg DA, Latchman DS (2005). Elevated expression of Brn-3a and Brn-3b transcription factors in systemic lupus erythematosus correlates with antibodies to Brn-3 and over-expression of Hsp90.. Arthritis and Rheumatism, 52, 1171 - 1179.
    • Green MRJ, Kennel AJM, Larche M, Seifert M, Isenberg DA, Salaman MR (2005). Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstrationof killing defect in patients.. Clinical and Experimental Immunology, 141, 165 - 173.
    • Rahman A, Bowman SJ, Giles IP, Ioannou Y, Isenberg DA (2005). Annus mirablilis - a guide to the 6th European Lupus Meeting 3-5 March 2005.. Rheumatology, 44, 962 - 964. doi:10.1093/rheumatology/keh702
    • Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, Ginzler EM, Urowitz EM, Gladman D, Fortin PR, Petri M, Edworthy S, Barr S, Gordon C, Bae SC, Sibley J, Isenberg DA, Rahman A, Aranow C, Dooley MA, Steinsson K, Nived O, Sturfelt G, Alarcon G, Senecal JL, Zummer M, Hanly J, Ensworth S, Pope J, El-Gabalawy H, McCarthy T, St Pierre Y, Ramsey-Goldman R, Clarke A (2005). An international cohort study of cancer in systemic lupus erythematosus.. Arthritis and Rheumatism, 52, 1481 - 1490.
    • Delgado-Alves J, RadwayBright E, Lee S, Grima B, Hothersall J, Ravirajan C, Isenberg D (2005). Antiphospholipid antibodies are induced by in vitro fertilization and correlate with paraoxonase activity and total antioxidant capacity of plasma in infertile women. Lupus, 14(5), 373 - 380.
    • Chambers S, Isenberg DA (2005). Autoimmunity - Systemic Lupus Erythematosus.. In Lotze MT, Thomson AW (Ed.), Measuring Immunity (pp. 505 - 514). : Elseiver.
    • Chambers SA, Isenberg DA (2005). Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.. Lupus, 14, 210 - 214.
    • Lazarus MN, Isenberg DA (2005). Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome.. Annals of the Rheumatic Diseases, 64, 1062 - 1064.
    • Edwards C, Isenberg DA (2005). Cyclophosphamide: time to say goodnight and goodbye?. Curr Rheum Rev, 1, 189 - 191.
    • Ripley BJM, Rahman MA, Isenberg DA, Latchman DS (2005). Elevated expression of the Brn-3a and Brn-3b transcription factors in Systemic Lupus Erythematosus correlates with antibodies to Brn-3 and overexpression of Hsp90. ARTHRITIS AND RHEUMATISM, 52(4), 1171 - 1179.
    • Fritsch C, Hoebeke J, Dali H, Ricchiuti V, Isenberg DA (2005). 52-kDa Ro/SSA epitopes preferentially recognised by antibodies from mothers of children with neonatal lupus and congenital heart block.. Arthritis Research and Therapy, 8(1), R4 - .
    • Delgado-Alves J, Mason LJ, Ames PRJ, Chen PP, Rauch J, Levine JS, Subang R, Isenberg DA (2005). Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model.. Rheumatology, 44, 1238 - 1244.
    • Peterson PL, Axford J, Isenberg DA (2005). Imaging in CNS Lupus.. In Gordon C, Ramsey-Goldman R (Ed.), Clinical Rheumatology, Best Practice Research: Systemic Lupus Erythematosus (pp. 727 - 740). : .
    • Goldblatt F, Isenberg DA (2005). New therapies for rheumatoid arthritis.. Clin Exp Immunol, 140, 195 - 204.
    • Chambers S, Isenberg DA (2005). Malignancy and rheumatic disease - a real association?. J Rheumatology, 32(1866), 1867 - .
    • Giles I, Isenberg D, A R, A (2005). Lessons from sequence analysis of monoclonal antiphospholipid antibodies.. In (Ed.), Hughes Syndrome: Antiphospholipid Syndrome (pp. - ). : Springer-Verlag.
    • Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed MA (2005). Decreased Lyn expression and translocation to lipid raft signalling domains in B-lymphocytes from patients with systemic lupus erythematosus.. Arthritis and Rheumatism, 52, 3955 - 3965.
    • Mason LJ, Isenberg DA (2005). The pathogenesis of systemic lupus erythematosus.. In Davison AM, Cameron JS, Grunfeld JP, Ponticelli C, Ritz E, Winearls CG, van Ypersele C (Ed.), Oxford Textbook of Clinical Nephrology (pp. 809 - 824). : Oxford University Press.
    • Goldblatt F, Isenberg DA (2005). New therapies for systemic lupus erythematosus.. Clin Exp Immunol, 140, 205 - 212.

    2004

    • Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A (2004). Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus.. Rheumatology, 43(7), 924 - 929.
    • Isenberg DA (2004). Making sure the treatment of myositis does not get 'lost in translation'.. Current Opinion in Rheumatology, 16, 665 - 667.
    • Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, Rozman B, Isenberg DA, Sturfelt G, Nived O, Turney JH, Venalis A, Adu D, Smolen JS, Emery P (2004). EULAR randomised controlled trial of pulse cyclophosphamide and methylpredniolone versus cotinuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.. Annals of the Rheumatic Diseases, 63, 525 - 529.
    • Hoffman IEA, Peene I, Mehus L, Huizinga TWJ, Cebecaver L, Isenberg DA, De Bosschere K, Hulstaert F, Veys E, De Keyser F (2004). Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus.. Annals of the Rheumatic Diseases, 63, 1155 - 1158.
    • Isenberg DA, Rahman A (2004). Systemic lupus erythematosus - management in adults. In Isenber DA, Maddison PJ, Woo P, Glass D, Breedveld FC (Ed.), Oxford Textbook of Rheumatology (pp. 842 - 847). : Oxford University Press.
    • Kazkaz H, Isenberg D, A (2004). Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases.. Curr Opin Pharmacol, 4, 398 - 401.
    • Gorman C, Leandro M, Isenberg DA (2004). Does B cell depletion have a role in the treatment of systemic lupus erythematosus?. Lupus, 13, 312 - 316.
    • Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA (2004). Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. Arthritis and Rheumatism, 50(3), 866 - 870. doi:10.1002/art.20103
    • Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004). Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy.. Journal of Experimental Medicine, 200(3), 277 - 285. doi:10.1084/jem.20040165
    • Haley J, Mason LJ, Nagl S, Giles I, Latchman DS, Isenberg DA, Rahman A (2004). Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. Molecular Immunology, 40(11), 745 - 758. doi:10.1016/j.molimm.2003.10.018
    • Isenberg DA (2004). Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus.. Lupus, 13, 881 - 885.
    • Mockridge CI, Rahman A, Buchan S, Hamblin T, Isenberg DA, Stevenson FK, Potter K, N (2004). Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. Autoimmunity, 37, 9 - 15.
    • Jury EC, Kabouridis PS, Flores-Borja F, Mageed RA, Isenberg DA (2004). Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus.. Journal of Clinical Investigation, 113(8), 1176 - 1187. doi:10.1172/JCI200420345
    • Wollaston SJ, Farewell VT, Isenberg DA, Gordon C, Merrill JT, Petri MA, Kalunian KC Systemic Lupus International Collaborating CSLICC (2004). Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.. Journal of Rheumatology, 31(12), 2390 - 2394.
    • Davies KA, Woo P (2004). Cells cytokines and other mediators. In Isenberg D, Maddison PJ, Woo P, Glass D, Breedveld FC (Ed.), Oxford Textbook of Rheumatology (pp. 399 - 410). : Oxford University Press.
    • Hall C, Woo P (2004). Diseases of bone and cartilage in children. In Isenberg DA, Maddison PJ, Woo P, Glass D, Breedveld FC (Ed.), Oxford Textbook of Rheumatology (pp. 1164 - 1172). : Oxford University Press.
    • Isenberg D, Maddison PJ, Woo P, Glass D, Breedveld FC (2004). Oxford textbook of rheumatology.
    • Glass D, Thompson S, Woo P (2004). Genomics and its relevance to rheumatology. In Isenberg D, Maddison PJ, Woo P, Glass D, Breedveld FC (Ed.), Oxford Textbook of Rheumatology (pp. 297 - 300). : Oxford University Press.
    • Isenberg DA (2004). Systemic lupus erythematosus and Sjogren's syndrome - historical perspective and ongoing concerns.. Arthritis Rheum, 50, 681 - 683.
    • Kumar S, Kalsi J, Bunting K, Ravirajan CT, Latchman DS, Pearl LH, Isenberg DA (2004). Fine binding characteristics of human autoantibodies-partial molecular characterization. Molecular Immunology, 41(5), 495 - 510.
    • Ravirajan CT, Wang YI, Matis LA, Papadaki L, Griffiths MH, Latchman DS, Isenberg DA (2004). Effect of neutralising antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. RHEUMATOLOGY, 43, 442 - 447.
    • Alves JD, Inanc , M , Diz-Kucukkaya , R , Grima , B , Soromento , F , Isenberg , D A (2004). Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and anti-phospholipid antibody syndrome-related thrombocytopenia.. European Journal of Internal Medicine, 15, 162 - 167.
    • Stoll T, Sutcliffe N, Mach J, Kilaghofer R, Isenberg D, A (2004). Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus - a 5 yr prospective study.. Rheumatology, 43, 1039 - 1044.
    • Mathews CJ, Isenberg DA (2004). What's new in autoimmune rheumatic diseases.. Medicine, 32, 1 - 4.
    • Mok MY, Jack DL, Lau CS, Fong DY, Turner MW, Isenberg DA, Lydyard PM (2004). Antibodies to mannose binding lectin in patients with systemic lupus erythematosus.. Lupus, 13(7), 522 - 528.
    • Gorman C, Isenberg D, A (2004). Atherosclerosis and lupus.. Rheumatology, 43, 943 - 945.
    • Abraham S, Begum S, Isenberg DA (2004). Hepatic manifestations of autoimmune rheumatic disease.. Ann Rheum Dis, 63, 123 - 129.
    • Clarke AE, Petri M, Manzi S, Isenberg DA, Gordon C, Senecal JL, Penrod J, Joseph L, St Pierre Y, Fortin PR, Sutcliffe N, Richard Goulet J, Choquette D, Grodzicky T, Esdaile JM Tri-Nation Study GROUP (2004). The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome.. Rheumatology, 43(8), 1016 - 1024.
    • Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Walport MJ, Vyse TJ (2004). Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus.. Human Molecular Genetics, 13(1), 137 - 147.
    • Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F International Myositis and Clinical Studies GIMACS (2004). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.. Rheumatology, 43(1), 49 - 54.

    2003

    • Giles IP, Isenberg DA, Latchman DS, Rahman A (2003). How do antiphospholipid antibodies bind beta2-glycoprotein I?. Arthritis and Rheumatism, 48(8), 2111 - 2121.
    • Karassa FB, Magliano M, Isenberg DA (2003). Suicide attempts in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 62(1), 58 - 60.
    • Giles IP, Haley J, Nagl S, Latchman DS, Chen PP, Chukwuocha RU, Isenberg DA, Rahman A (2003). Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. Molecular Immunology, 40(1), 49 - 60. doi:10.1016/S0161-5890(03)00100-7
    • Giles IP, Haley JD, Nagl S, Isenberg DA, Latchman DS, Rahman A (2003). A systematic analysis of sequences of human antiphospholipid and anti-2 glycoprotein I antibodies reveals the importance of somatic mutations and certain sequence motifs. Seminars in Arthritis and Rheumatism, 32, 246 - 265.
    • Giles I, Haley J, Isenberg DA, Latchman DS, Nagl S, Rahman A (2003). Systematic review of sequences of human antiphospholipid and anti-beta 2 glycoprotein I antibodies (aPL).. Seminars in Arthritis and Rheumatism, 32, 246 - 265.
    • Jury EC, Kabouridis PS, Abba A, Mageed RA, Isenberg DA (2003). Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis and Rheumatism, 48(5), 1343 - 1354. doi:10.1002/art.10978
    • Giles IP, Isenberg DA, Latchman DS, Rahman A (2003). How do antiphospholipid antibodies bind  2-glycoprotein I. Arthritis and Rheumatism, 48, 2111 - 2121.
    • Giles IP, Haley J, Nagl S, Latchman DS, Chen PP, Chukwuocha RU, Isenberg DA, Rahman A (2003). Relative importance of different aPL derived heavy and light chains in the binding of aPL to cardiolipin. Molecular Immunology, 40, 49 - 60.
    • Davies AK, Woo P (2003). Cells cytokines and other mediators. In Maddison PJ, Isenberg DA, Woo P, Glass DN (Ed.), Oxford Textbook of Rheumatology (pp. 399 - 401). : Oxford University Press.
    • Hall C, Woo P (2003). Disease of bone and cartilage in children. In Isenberg D, Maddison PJ, Woo P, Glass D, Breedveld FC (Ed.), Oxford Textbook of Rheumatology (pp. 1164 - 1173). : Oxford University Press.
    • Rahman A, Isenberg DA (2003). Systemic lupus erythematosus and related disorders.. In (Ed.), Oxford Textbook of Medicine (pp. 80 - 90). : Oxford University Press.
    • Manson JJ, Isenberg DA (2003). The pathogenesis of systemic lupus erythematosus. NETHERLANDS JOURNAL OF MEDICINE, 61(11), 343 - 346.
    • Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, Lachenbruch PA, Miller FW (2003). Defining Clinical Improvement in Adult and Juvenile Myositis. Journal of Rheumatology, 30(3), 603 - 617.
    • Kumar S, Nagl S, Kalsi JK, Ravirajan CT, Athwal D, Latchman DS, Pearl LH, Isenberg DA (2003). Anti-cardiolipin/beta-2 glycoportein activities co-exist on human anti-DNA antibody light chains. Molecular Immunology, 40, 517 - 530. doi:10.1016/S0161-5890(03)00225-6
    • Wijeyekoon JB, Isenberg DA (2003). Treatment focus: systemic lupus erythematosus.. Hospital Pharmacy Europe, (April/May), 31 - 34.
    • Dayal NA, Isenberg DA (2003). Endstage renal failure in primary antiphospholipid syndrome--case report and review of literature. Rheumatology, 42(9), 1128 - 1129.
    • Giles IP, Isenberg DA (2003). Autoimmune rheumatic diseases and vasculitis..
    • Sultan SM, Begum S, Isenberg DA (2003). Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology, 42(2), 230 - 234.
    • Ramsey-Goldman R, Isenberg DA (2003). Systemic lupus erythematosus measures.. Arthritis Care and Research, 49, S225 - S233.
    • Sen D, Isenberg DA (2003). Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus, 12(9), 651 - 658.
    • Miller FW, Rider LG, Plotz PH, Isenberg DA, Oddis CV (2003). Diagnostic criteria for polymyositis and dermatomyositis. The Lancet, 362(9397), 1762 - 1763.
    • Bates RL, Payne SJ, Drury SL, Nelson PN, Isenberg DA, Murphy JJ, Frampton G (2003). The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus. Lupus, 12(8), 617 - 622.
    • Manson JJ, Isenberg DA (2003). Antiphospholipid syndrome. The International Journal of Biochemistry and Cell Biology, 35(7), 1015 - 1020.
    • Silva CA, Sultan SM, Isenberg DA (2003). Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. Rheumatology, 42(10), 1168 - 1172.
    • Gorman C, Leandro M, Isenberg DA (2003). B cell depletion in autoimmune disease.. Arthritis Res Ther, 5, S17 - S21.
    • Delgado AJ, Kumar S, Isenberg DA (2003). Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology, 42(7), 893 - 899.
    • Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA (2003). Definition and treatment of lupus flares measured by the BILAG index. Rheumatology, 42(11), 1372 - 1379.
    • Giles IP, Haley JD, Nagl S, Isenberg DA, Latchman DS, Rahman A (2003). A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. Seminars in Arthritis and Rheumatism, 32(4), 246 - 265.

    2002

    • Pyne D, Isenberg DA (2002). Autoimmune thyroid disease in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 61(1), 70 - 72.
    • Karassa FB, Magliano M, Isenberg DA (2002). Suicide attempts in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 62(1), 58 - 60.
    • Mageed RA, Isenberg DA (2002). Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production. Lupus, 11(12), 850 - 855.
    • Potter KN, Mockridge CI, Rahman A, Buchan S, Hamblin T, Davidson B, Isenberg DA, Stevenson FK (2002). Disturbances in peripheral blood B cell subpopulations in autoimmune patients. Lupus, 11(12), 872 - 877.
    • Isenberg DA (2002). Autoimmune diseases: an introduction.. Medicine, 20, 1 - 2.
    • Anand A, Dean GS, Quereshi K, Isenberg DA, Lydyard PM (2002). Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: activation markers. Lupus, 11(8), 493 - 500.
    • Begum S, Li C, Wedderburn LR, Blackwell V, Isenberg DA (2002). Concurrence of sarcoidosis and systemic lupus erythematosus in three patients. Clinical and Experimental Rheumatology, 20(4), 549 - 552.
    • Linnik M, Staines NA, Berden J, Isenberg DA (2002). Workshop report on some new ideas about the treatment of systemic lupus erythematosus. Lupus, 11(12), 793 - 796.
    • Isenberg DA, Ehrenstein M, Rahman A (2002). 'Oh come all ye faithful'; acquiring and maintaining a cohort.. Rheumatology, 41, 5 - 6.
    • Tzioufas AG, Wassmuth R, Dafni UG, Guialis A, Haga HJ, Isenberg DA, Jonsson R, Kalden JR, Kiener H, Sakarellos C, Smolen JS, Sutcliffe N, Vitali C, Yiannaki E, Moutsopoulos HM (2002). Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a European multicentre study. Annals of the Rheumatic Diseases, 61(5), 398 - 404.
    • Choy EH, Isenberg DA (2002). Treatment of dermatomyositis and polymyositis. RHEUMATOLOGY (OXFORD), 41(1), 7 - 13.
    • Maddison P, Farewell V, Isenberg D, Aranow C, Bae SC, Barr S, Buyon J, Fortin P, Ginzler E, Gladman D, Hanly J, Manzi S, Nived O, Petri M, Ramsey-Goldman R, Sturfelt G (2002). The rate and pattern of organ damage in late onset systemic lupus erythematosus. Journal of Rheumatology, 29(5), 913 - 917.
    • Papageorgiou K, Isenberg DA, Latchman DS (2002). Optimisation of herpes simplex virus-based vectors for delivery to human peripheral blood mononuclear cells. Journal of Immunological Methods, 270(2), 235 - 246.
    • Dayal NA, Isenberg DA (2002). SLE/myositis overlap: are the manifestations of SLE different in overlap disease?. Lupus, 11(5), 293 - 298.
    • Karassa FB, Isenberg DA (2002). Spontaneous rupture of the spleen: an unusual complication of systemic lupus erythematosus. Lupus, 10(12), 876 - 878.
    • Dean GS, Anand A, Blofeld A, Isenberg DA, Lydyard PM (2002). Characterization of CD3+ CD4- CD8 - (double negative) T cells in patients with Systemic Lupus Erythematosus: production of IL-4. Lupus, 11(8), 501 - 507.
    • Moss KE, Ioannou Y, Sultan SM, Haq I, Isenberg DA (2002). Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Annals of the Rheumatic Diseases, 61(5), 409 - 413.
    • MacGowan JR, Ellis S, Griffiths M, Isenberg DA (2002). Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. RHEUMATOLOGY (OXFORD), 41(9), 981 - 987.
    • Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002). Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. RHEUMATOLOGY (OXFORD), 41(1), 22 - 26.
    • Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS (2002). Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis and Rheumatism, 46(12), 3143 - 3150. doi:10.1002/art.10623
    • Anand A, Dean GS, Quereshi K, Isenberg DA, Lydyard PM (2002). Characterisation of CD3+, CD4-, CD8- (double negative) T cells in patients with systemic lupus erythematosus (SLE): activation markers. Lupus, 11, 493 - 500.
    • Rhodes DA, Ihrke G, Reinicke AT, Malcherek G, Towey M, Isenberg DA, Trowsdale J (2002). The 52 000 MW Ro/SS-A autoantigen in Sjogren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology, 106(2), 246 - 256.
    • Ioannou Y, Isenberg DA (2002). Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgraduate Medical Journal, 78(924), 599 - 606.
    • Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA (2002). Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. RHEUMATOLOGY (OXFORD), 41(10), 1133 - 1137.
    • Delgado AJ, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA, Noorouz-Zadeh J (2002). Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis and Rheumatism, 46(10), 2686 - 2694. doi:10.1002/art.10542
    • Hassan AB, Lundberg IE, Isenberg D, Wahren-Herlenius M (2002). Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 31(3), 133 - 139.
    • Isenberg DA, Smeenk R (2002). Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now?. Lupus, 11, 797 - 800.
    • Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002). An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis and Rheumatism, 46(10), 2673 - 2677. doi:10.1002/art.10541
    • Haq I, Isenberg DA (2002). How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice?. Best Practice and Research Clinical Rheumatology, 16(2), 181 - 194.
    • Dayal NA, Gordon C, Tucker L, Isenberg DA (2002). The SLICC damage index: past, present and future. Lupus, 11(4), 261 - 265.
    • Haq I, Isenberg DA (2002). Myositis and swollen knees: disease or treatment complication?. Annals of the Rheumatic Diseases, 61(6), 544 - 546.
    • Dean GS, Isenberg DA (2002). Detection of anticardiolipin antibodies. Clinical and Experimental Rheumatology, 20(2), 258 - 259.
    • Haq I, Isenberg DA (2002). Systemic lupus erythematosus.. Medicine, 30, 6 - 12.
    • Isenberg D, Leckie MJ (2002). Biological treatments for systemic lupus erythematosus. Scandinavian Journal of Rheumatology, 31(4), 187 - 191.
    • Ravirajan CT, Isenberg DA (2002). Transgenic models of tolerance and autoimmunity: with special reference to systemic lupus erythematosus. Lupus, 11(12), 843 - 849.
    • Kumar S, Kalsi JK, Ravirajan CT, Latchman DS, Pearl LH, Isenberg DA (2002). Molecular expression systems for anti-DNA antibodies--2. Lupus, 11(12), 833 - 842.
    • Magliano M, Isenberg DA, Hillson J (2002). Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?. Arthritis and Rheumatism, 46(8), 1997 - 2009.

    2001

    • Karassa FB, Isenberg DA (2001). Spontaneous rupture of the spleen: an unusual complication of systemic lupus erythematosus. Lupus, 10(12), 876 - 878.
    • Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA (2001). Total costs and predictors of costs in patients with systemic lupus erythematosus. RHEUMATOLOGY (OXFORD), 40(1), 37 - 47.
    • Dodds WN, Isenberg DA (2001). UK regional rheumatology meetings. RHEUMATOLOGY (OXFORD), 40(12), 1423 - .
    • Karassa FB, Isenberg DA (2001). Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. New England Journal of Medicine, 344(5), 382 - 383.
    • Silva C, Isenberg DA (2001). Aetiology and pathology of systemic lupus erythematosus.. Hospital Pharmacist, 8, 62 - 68.
    • Tyrrell-Price J, Lydyard PM, Isenberg DA (2001). The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clinical and Experimental Immunology, 124(1), 118 - 125.
    • Rahman A, Haley J, Radway-Bright E, Nagl S, Low DG, Latchman DS, Isenberg DA (2001). The importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies. Journal of Molecular Biology, 307(1), 149 - 160. doi:10.1006/jmbi.2000.4491
    • Salaman MR, Mawer DP, Hogarth MB, Seifert MH, Isenberg DA (2001). Counter-proliferative effects of nucleosomal antigens in cultures from lupus patients. Lupus, 10(5), 332 - 339.
    • Moss KE, Isenberg DA (2001). Comparison of renal disease severity and outcome in patients with primary anti-phospholipid syndrome, anti-phospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone.. Rheumatology, 40(8), 863 - 867.
    • Price EJ, Hay EM, Isenberg DA (2001). Research and training review of the use of LAS, LAT and flexible training positions. RHEUMATOLOGY (OXFORD), 40(12), 1413 - 1415.
    • Isenberg DA, Gladman D (2001). The Systemic Lupus International Collaborating Clinics Group--origins and outcomes. Lupus, 10(5), 375 - 377.
    • Ripley BJ, Isenberg DA, Latchman DS (2001). Elevated Levels of the 90 kDa Heat Shock Protein (hsp90) in SLE Correlate with Levels of IL-6 and Autoantibodies to hsp90. Journal of Autoimmunity, 17(4), 341 - 346.
    • Donohue S, Mackie IJ, Isenberg DA, Machin SJ (2001). Anti-prothrombin antibodies; assay conditions and clinical associations in the anti-phospholipid syndrome.. British Journal of Haematology, 113, 544 - 549.
    • Bickerstaff MCM, Isenberg DA (2001). An overview of SLE.. Rheumatology in the kidney, Oxford University Press, , 3 - 16.
    • Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg DA (2001). Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. RHEUMATOLOGY (OXFORD), 40(11), 1262 - 1273.
    • Dayal NA, Isenberg DA (2001). Assessment of inflammatory myositis. Current Opinion in Rheumatology, 13(6), 488 - 492.
    • Mason LJ, Ravirajan CT, Latchman DS, Isenberg DA (2001). A human anti-dsDNA monoclonal antibody caused hyaline thrombi formation in kidneys of 'leaky' SCID mice. Clinical and Experimental Dermatology, 126(1), 137 - 142.
    • Dean GS, Isenberg DA (2001). Detection of anticardiolipin antibodies in culture supernatants. Clinical and Experimental Rheumatology, 19(3), 251 - 257.
    • Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ (2001). Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Annals of the Rheumatic Diseases, 60(1), 67 - 68.
    • Leandro MJ, Isenberg DA (2001). Rheumatic diseases and malignancy--is there an association?. Scandinavian Journal of Rheumatology, 30(4), 185 - 188.
    • Brouwer R, Hengstman GJ, Vree EW, Ehrfeld H, Bozic B, Ghirardello A, Grondal G, Hietarinta M, Isenberg D, Kalden JR, Lundberg I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wikman A, Seelig HP, van Engelen BG, van Venrooij WJ (2001). Autoantibody profiles in the sera of European patients with myositis. Annals of the Rheumatic Diseases, 60(2), 116 - 123.
    • Alberdi F, Dadone J, Ryazanov A, Isenberg DA, Ravirajan C, Reichlin M (2001). Cross-reaction of lupus anti-dsDNA antibodies with protein translation factor EF-2. Clinical Immunology, 98(2), 293 - 300.
    • Sharma A, Isenberg DA, Diamond B (2001). Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. Journal of Autoimmunity, 16(4), 479 - 484.
    • Kumar S, Kalsi J, Latchman DS, Pearl LH, Isenberg DA (2001). Expression of the Fabs of human auto-antibodies in Escherichia coli: optimization and determination of their fine binding characteristics and cross-reactivity. Journal of Molecular Biology, 308(3), 527 - 539.
    • Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ (2001). Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).. British Journal of Haematology, 115, 451 - 459.
    • Giles I, Isenberg D (2001). Lupus in the family--analysis of a cohort followed from 1978 to 1999. Lupus, 10(1), 38 - 44.
    • Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA (2001). An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. RHEUMATOLOGY (OXFORD), 40(12), 1405 - 1412.
    • Leandro MJ, Isenberg DA (2001). Investigating headaches in patients with systemic lupus erythematosus.. Acta Rheum Port, 26, 65 - 72.
    • Joseph JE, Harrison P, MacKie IJ, Isenberg DA, MacHin SJ (2001). Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. British Journal of Haematology, 115(2), 451 - 459.
    • Isenberg DA, Katz D, Maddison P, Watts R, Tucker L, Cooke A (2001). Induction of anti-DNA antibodies: commentary on article by Satake et al. Lupus, 10, 63 - 65.
    • Dean GS, Anand A, Bofeld A, Isenberg DA, Lydyard PM (2001). Functional characterisation of double negative T cells in system lupus erythematosus: measurement of spontaneous and mitogen-stimulated in vitro IL4 production. Lupus, 10(Suppl), - .

    2000

    • Sultan SM, Ioannou Y, Isenberg DA (2000). Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. RHEUMATOLOGY (OXFORD), 39(10), 1147 - 1152.
    • Mok MY, Farewell VT, Isenberg DA (2000). Risk factors for avascular necrosis of bone in patients with systemic lupus erythematosus: is there a role for antiphospholipid antibodies?. Annals of the Rheumatic Diseases, 59(6), 462 - 467.
    • Frampton G, Moriya S, Pearson JD, Isenberg DA, Ward FJ, Smith TA, Panayiotou A, Staines NA, Murphy JJ (2000). Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen. RHEUMATOLOGY (OXFORD), 39(10), 1114 - 1120.
    • McDonagh JE, Isenberg DA (2000). Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 59(3), 230 - 232.
    • Stoll T, Sutcliffe N, Klaghofer R, Isenberg DA (2000). Do present damage and health perception in patients with systemic lupus erythematosus predict extent of future damage?: a prospective study. Annals of the Rheumatic Diseases, 59(10), 832 - 835.
    • Lydyard PM, Youinou PY, Isenberg DA (2000). Apoptosis and autoimmune diseases. In Ruffolo RR, Walsh F (Ed.), Apoptosis in health and disease (pp. 17 - 31). : Harwood Academic Publishers.
    • Isenberg DA, Gordon C (2000). From BILAG to BLIPS--disease activity assessment in lupus past, present and future. Lupus, 9(9), 651 - 654.
    • Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA (2000). Cytokines and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 59(4), 243 - 251.
    • Sutcliffe N, Smith C, Speight PM, Isenberg DA (2000). Mucosa-associated lymphoid tissue lymphomas in two patients with rheumatoid arthritis on second-line agents, and secondary Sjogren's syndrome. Rheumatology, 39(2), 185 - 188.
    • Moore AD, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, St Pierre Y, Joseph L, Penrod J, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Esdaile JM, Clarke AE (2000). The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. Arthritis and Rheumatism, 43(6), 1410 - 1418.
    • Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Petri M, Nived O, Snaith M, Sturfelt G (2000). The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. Journal of Rheumatology, 27(2), 373 - 376.
    • Pittoni V, Ravirajan CT, Donohoe S, MacHin SJ, Lydyard PM, Isenberg DA (2000). Human monoclonal anti-phospholipid antibodies selectively bind to membrane phospholipid and beta2-glycoprotein I (beta2-GPI) on apoptotic cells. Clinical and Experimental Immunology, 119(3), 533 - 543.
    • Tench CM, Isenberg DA (2000). The variation in anti-ENA characteristics between different ethnic populations with systemic lupus erythematosus over a 10-year period. Lupus, 9(5), 374 - 376.
    • Eftekhari P, Salle L, Lezoualc'h F, Mialet J, Gastineau M, Briand JP, Isenberg DA, Fournie GJ, Argibay J, Fischmeister R, Muller S, Hoebeke J (2000). Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. European Journal of Immunology, 30(10), 2782 - 2790.
    • Isenberg DA (2000). Lupus-molecular and cellular pathogenesis. Annals of the Rheumatic Diseases, 59(3), 172A - 172.
    • Radway-Bright EL, Ravirajan CT, Isenberg DA (2000). The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, systemic lupus erythematosus and their relatives and spouses. RHEUMATOLOGY (OXFORD), 39(4), 427 - 431.
    • Kumar S, Kalsi J, Ravirajan CT, Rahman A, Athwal D, Latchman DS, Isenberg DA, Pearl LH (2000). Molecular cloning and expression of the Fabs of human autoantibodies in Escherichia coli. Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab. Journal of Biological Chemistry, 275(45), 35129 - 35136.

    1999

    • Frank MB, McCubbin V, Trieu E, Wu Y, Isenberg DA, Targoff IN (1999). The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. Journal of Autoimmunity, 12(2), 137 - 142.
    • Hussain S, Isenberg DA (1999). Autoimmune rheumatic diseases and the heart. Hospital Medicine, 60(2), 95 - 99.
    • Isenberg DA, Liang MH (1999). CNS lupus--where do we go from here? [editorial; comment]. Lupus, 8(1), 1 - 2.
    • (1999). A longitudinal study of anticardiolipin antibody levels and cognitive functioning in SLE. Arthritis and Rheumatism, 42, 735 - 741.
    • Norsworthy P, Theodoridis E, Botto M, Athanassiou P, Beynon H, Gordon C, Isenberg D, Walport MJ, Davies KA (1999). Overrepresentation of the Fcgamma receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. Arthritis and Rheumatism, 42(9), 1828 - 1832.
    • Rahman A, Stevenson FK, Isenberg DA (1999). B cells: formation and structure of autoantibodies. In Gaston JSH (Ed.), Rheumatic disease - immunological mechanisms and prospects for new therapies (pp. 61 - 78). : Cambridge University Press.
    • Latchman DS, Rahman A, Isenberg DA (1999). Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. Seminars in arthritis and Rheumatism, 28, 141 - 154.
    • Ravirajan CT, Pittoni V, Isenberg DA (1999). Apoptosis in human autoimmune diseases. International Review of Immunology, 18(5-6), 563 - 589.
    • Crawley E, Woo P, Isenberg DA (1999). Single nucleotide polymorphic haplotypes of the interleukin-10 5' flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. Arthritis and Rheumatism, 42(9), 2017 - 2018.
    • Rahman A, Latchman DS, Isenberg DA (1999). Sequence features of monoclonal anti-phospholipid antibodies. Arthritis and Rheumatism, 42, 1783 - 1784.
    • Pourmand N, Wahren Herlenius M, Gunnarsson I, Svenungsson E, Lofstrom B, Ioannou Y, Isenberg DA, Magnusson CG (1999). Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjogren's syndrome and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 58(10), 623 - 629.
    • Mason LJ, Timothy LM, Isenberg DA, Kalsi JK (1999). Immunization with a peptide of Sm B/B' results in limited epitope spreading but not autoimmune disease. The Journal of Immunology, 162(9), 5099 - 5105.
    • Choy EH, Rankin EC, Kassimos D, Vetterlein O, Garyfallos A, Ravirajan CT, Sopwith M, Eastell R, Kingsley GH, Isenberg DA, Panayi GS (1999). The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis. Journal of Rheumatology, 26(11), 2310 - 2317.
    • Ioannou Y, Sultan S, Isenberg DA (1999). Myositis overlap syndromes. Current Opinion in Rheumatology, 11(6), 468 - 474.
    • Ioannou Y, Isenberg DA (1999). Immunisation of patients with systemic lupus erythematosus: the current state of play. Lupus, 8(7), 497 - 501.
    • Situnayake RD, Rahman A, Bowman S I, D G, C (1999). Systemic lupus erythematosus into the next millennium: looking into the crystal ball. Lupus, 8, 716 - 722.
    • Rahman A, Isenberg DA (1999). Autoantibodies in lupus nephritis. In Lewis EJ (Ed.), Lupus Nephritis (pp. - ). : Oxford University Press.
    • Ames PR, Alves J, Murat I, Isenberg DA, Nourooz Zadeh J (1999). Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology, 38(6), 529 - 534.
    • Clarke AE, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, St Pierre Y, Joseph L, Penrod J, Fortin PR, Sutcliffe N, Goulet JR, Choquette D, Grodzicky T, Danoff DS, Ho V, Esdaile JM (1999). An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. Journal of Rheumatology, 26(7), 1500 - 1511.
    • Crawley E, Isenberg D, Woo P, Kay R (1999). Interleukin-10 promoter polymorphism and lupus nephritis: comment on the article by Mok et al [letter; comment]. Arthritis and Rheumatism, 42(3), 590 - 593.
    • Radway Bright EL, Inanc M, Isenberg DA (1999). Animal models of the antiphospholipid syndrome. Rheumatology, 38(7), 591 - 601.
    • Ripley BJM, Stephanou A, Isenberg DA, Latchman DS (1999). Interleukin-10 activates heat shock protein 90 gene expression. Immunology, 97, 226 - 231.
    • Carvalho D, Savage CO, Isenberg D, Pearson JD (1999). IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocr. Arthritis and Rheumatism, 42(4), 631 - 640.
    • Woo P, Martin K (1999). Juvenile idiopathic arthritis. In Isenberg D, Miller JJ (Ed.), Adolescent Rheumatology (pp. 71 - 94). : Martin Dunitz.
    • Isenberg D, Ramsey Goldman R (1999). Assessing patients with lupus: towards a drug responder index. Rheumatology, 38(11), 1045 - 1049.

    1998

    • Rahman MAA, Kettleborough CA, Latchman DS, Isenberg DA (1998). Properties of whole human IgG molecules produced by the expression of cloned anti-DNA antibody cDNA in mammalian cells. Journal of Autoimmunity, 11(6), 661 - 669.
    • Pittoni V, Isenberg D (1998). Apoptosis and antiphospholipid antibodies. SEMIN ARTHRITIS RHEUM, 28(3), 163 - 178.
    • Rahman A, Latchman DS, Isenberg DA (1998). The role of in vitro expression systems in the investigation of antibodies to DNA. Seminars in Arthritis and Rheumatism, 28(2), 130 - 139.
    • Ravirajan CT, Rahman MA, Papadaki L, Griffiths M, Kalsi J, Martin ACR, Ehrenstein MR, Latchman DS, Isenberg DA (1998). Genetic Structural and Functional Properties of a Human IgG Anti-DNA Antibody. European Journal of Immunology, 28, 339 - 350.
    • Stephanou A, Isenberg DA, Akira S, Kishimoto T, Latchman DS (1998). The nuclear factor interleukin-6 (NF-IL6) and signal transducer and activator of transcription-3 (STAT-3) signalling pathways co-operate to mediate the activation of the hsp90beta gene by interleukin-6 but have opposite effects on its inducibility by heat. BIOCHEM J, 330(Pt 1), 189 - 195.
    • Ravirajan CT, Rahman MA, Papadaki L, Griffiths MH, Kalsi J, Martin AC, Ehrenstein MR, Latchman DS, Isenberg DA (1998). Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. EUR J IMMUNOL, 28(1), 339 - 350.
    • Rahman A, Latchman DS, Isenberg DA (1998). Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. Seminars in Arthritis and Rheumatism, 28(3), 141 - 154.
    • Karray S, Juompan L, Maroun RC, Isenberg D, Silverman GJ, Zouali M (1998). Structural basis of the gp120 superantigen-binding site on human immunoglobulins. The Journal of Immunology, 161(12), 6681 - 6688.
    • Mockridge CI, Chapman CJ, Spellerberg MB, Sheth B, Fleming TP, Isenberg DA, Stevenson FK (1998). Sequence analysis of V(4-34)-encoded antibodies from single B cells of two patients with systemic lupus erythematosus (SLE). CLIN EXP IMMUNOL, 114(1), 129 - 136.
    • Decker P, Briand JP, de Murcia G, Pero RW, Isenberg DA, Muller S (1998). Zinc is an essential cofactor for recognition of the DNA binding domain of poly(ADP-ribose) polymerase by antibodies in autoimmune rheumatic and bowel diseases. ARTHRITIS RHEUM, 41(5), 918 - 926.
    • Mason LJ, Isenberg DA (1998). Immunopathogenesis of SLE. BAILLIERES CLIN RHEUMATOL, 12(3), 385 - 403.
    • Blake DR, Hazleman B, Cooper C, Isenberg D, Edwards RL (1998). From criticism to creativity: the genesis of the ARC/BSR Clinical Trials Group [editorial]. British Journal of Rheumatology, 37(11), 1146 - 1147.
    • Isenberg DA, McClure C, Farewell V, Spellerberg M, Williams W, Cambridge G, Stevenson F (1998). Correlation of 9G4 idiotope with disease activity in patients with systemic lupus erythematosus. ANN RHEUM DIS, 57(9), 566 - 570.
    • Stephanou A, Latchman DS, Isenberg DA (1998). The regulation of heat shock proteins and their role in systemic lupus erythematosus. SEMIN ARTHRITIS RHEUM, 28(3), 155 - 162.
    • Inanc M, Donohoe S, Ravirajan CT, Radway-Bright EL, Mackie I, Machin S, Isenberg DA (1998). Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. British Journal of Rheumatology, 37(10), 1089 - 1094.
    • Latchman DS, Stephanou A, Conroy S, Isenberg DA, Maione D, Poli V, Ciliberto G (1998). Elevation of IL-6 in transgenic mice results in increased levels of the 90kDa heat shock protein (hsp90) and the production of anti hsp90 antibodies. Journal of Autoimmunity, 11, 249 - 253.
    • Latchman DS, Stephanou A, Isenberg DA (1998). The regulation of heat shock protein and its role in SLE. Seminars in arthritis and Rheumatism, 28, 155 - 162.
    • Latchman DS, Stephanou A, Isenberg DA, Akira S, Kishimoto T (1998). The NF-IL6 and STAT-3 signalling pathways co-operate to mediate the activation of the hsp90( gene by IL-6 but have opposite effects on its inducibility by heat shock. Biochemical Journal, 330, 189 - 195.
    • Williams WM, Isenberg DA (1998). Naturally occurring anti-idiotypic antibodies reactive with anti-DNA antibodies in systemic lupus erythematosus. LUPUS, 7(3), 164 - 175.
    • Bourne T, Zukowska C, Salaman MR, Seifert MH, Isenberg DA (1998). Spontaneous immunoglobulin-producing capacity of cultures from lupus patients and normal donors following depletion of cells expressing CD19 or CD38. CLIN EXP IMMUNOL, 111(3), 611 - 616.
    • Sutcliffe N, Stoll T, Pyke S, Isenberg DA (1998). Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjogren's syndrome (SS), and primary SS. J RHEUMATOL, 25(1), 63 - 68.
    • Hakim AJ, Machin SJ, Isenberg DA (1998). Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. SEMIN ARTHRITIS RHEUM, 28(1), 20 - 25.
    • Richter C, Steiner G, Smolen JS, Isenberg DA (1998). Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subset. British Journal of Rheumatology, 37(4), 421 - 424.

    1997

    • Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, Hanly JG, Isenberg DA, Kalunian K, Nived O, Petri M, Sanchez G, Snaith M, Sturfelt G (1997). The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. ARTHRITIS RHEUM, 40(5), 809 - 813.
    • Woo P (1997). Molecular genetics and their relevance to rheumatology. In Madison PJ, Isenberg DA, Woo P, Glass DN (Ed.), Oxford Textbook of Rheumatology (pp. 347 - 352). : Oxford University Press.
    • Woo P, Lovell D (1997). Growth and skeletal maturation. In Madison PJ, Isenberg DA, Woo P, Glass DN (Ed.), Oxford University Press (pp. 72 - 88). : Oxford University Press.
    • Wilson C, Thakore A, Isenberg D, Ebringer A (1997). Correlation between anti-Proteus antibodies and isolation rates of P. mirabilis in rheumatoid arthritis. RHEUMATOL INT, 16(5), 187 - 189.
    • Stoll T, Stucki G, Gordon C, Isenberg DA (1997). A damage index for lupus patients--where are we now? [editorial]. LUPUS, 6(3), 219 - 222.
    • Isenberg DA, Garton M, Reichlin MW, Reichlin M (1997). Long-term follow-up of autoantibody profiles in black female lupus patients and clinical comparison with Caucasian and Asian patients. BR J RHEUMATOL, 36(2), 229 - 233.
    • Chinn RJ, Wilkinson ID, Hall-Craggs MA, Paley MN, Shortall E, Carter S, Kendall BE, Isenberg DA, Newman SP, Harrison MJ (1997). Magnetic resonance imaging of the brain and cerebralproton spectroscopy in patients with systemic lupuserythematosus. Arthritis and Rheumatism, 40(1), 36 - 46.
    • Sutcliffe N, Morris V, Gomperts B, Brazier DJ, Isenberg DA, Cambridge G (1997). Relationship between the development of blindness in Churg-Strauss syndrome and anti-myeloperoxidase antibodies. BR J RHEUMATOL, 36(2), 273 - 275.
    • Winska-Wiloch H, Muller S, Katz DR, Wilkinson L, Hutchings PR, Isenberg DA (1997). Immunogenic properties of synthetic fragments of Sm-D protein in normal and lupus mice. Lupus, 6(8), 656 - 667.
    • Stoll T, Gordon C, Seifert B, Richardson K, Malik J, Bacon PA, Isenberg DA (1997). Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J RHEUMATOL, 24(8), 1608 - 1614.
    • Erkeller-Yuksel FM, Lydyard PM, Isenberg DA (1997). Lack of NK cells in Lupus patients with renal involvement. Lupus, 6(9), 708 - 712.
    • Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA (1997). Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J RHEUMATOL, 24(2), 309 - 313.
    • Garton MJ, Isenberg DA (1997). Clinical features of lupus myositis versus idiopathic myositis: a review of 30 cases. BR J RHEUMATOL, 36(10), 1067 - 1074.
    • Inanc M, Radway B, Isenberg DA (1997). beta 2-Glycoprotein I and anti-beta 2-glycoprotein I antibodies: where are we now?. BR J RHEUMATOL, 36(12), 1247 - 1257.
    • Ravirajan CT, Rahman MA, Lucienne P, Kalsi JK, Martin ACR, Ehrenstein MR, Griffiths M, Latchman DS, Isenberg DA (1997). Genetic structural and functional properties of a human IgG anti-DNA autoantibody. European Journal of Immunology, 28, 339 - 350.
    • Fishman D, Isenberg DA (1997). Splenic involvement in rheumatic diseases. SEMIN ARTHRITIS RHEUM, 27(3), 141 - 155.
    • (1997). Oxford Textbook of Rheumatology.
    • Glass D, Woo P (1997). Nosology of chronic inflammatory rheumatic diseases. In Madison PJ, Isenberg DA, Woo P, Gladd DN (Ed.), Oxford Textbook of Rheumatology (pp. 843 - 848). : Oxford University Press.
    • Rose LM, Latchman DS, Isenberg DA (1997). Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review. BR J RHEUMATOL, 36(2), 158 - 163.
    • Isenberg DA (1997). Autoantibodies: markers of disease or pathogenic?. ANN N Y ACAD SCI, 823, 256 - 262.
    • Isenberg DA, Ravirajan CT, Rahman A, Kalsi J (1997). The role of antibodies to DNA in systemic lupus erythematosus--a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Lupus, 6(3), 290 - 304.
    • McDonagh JE, Khamashta MA, Menon S, Rahman A, Isenberg DA (1997). A young woman with SLE: diagnostic and therapeutic challenges. LUPUS, 6(8), 633 - 637.
    • Menon S, Rahman MA, Ravirajan CT, Kandiah D, Longhurst CM, McNally T, Williams WM, Latchman DS, Isenberg DA (1997). The production, binding characteristics and sequence analysis of four human IgG monoclonal antiphospholipid antibodies. Journal of Autoimmunity, 10(1), 43 - 57.
    • Stephanou A, Amin V, Isenberg DA, Akira S, Kishimoto T, Latchman DS (1997). Interleukin 6 activates heat-shock protein 90 beta gene expression. Biochemical Journal, 321(1), 103 - 106.
    • Rose LM, Latchman DS, Isenberg DA (1997). Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus, 6, 717 - 722.
    • Isenberg DA (1997). Systemic lupus erythematosus: immunopathogenesis and the card game analogy. J RHEUMATOL SUPPL, 48, 62 - 66.
    • Fox RA, Isenberg DA (1997). Human immunodeficiency virus infection in systemic lupus erythematosus. ARTHRITIS RHEUM, 40(6), 1168 - 1172.
    • Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H, Singh R, Wallace DJ, Kitridou RC, Chen SL, Shen N, Song YW, Isenberg DA, Yu CL, Hahn BH, Rotter JI (1997). Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J CLIN INVEST, 99(4), 725 - 731.
    • Woo P (1997). Genomics and it's relevance to rheumatology. In Isenberg DA, Maddison PJ, Woo P, Glass D, Breedveld FC (Ed.), Ocford Textbook of Rheumatology (pp. 297 - 300). : Oxford University Press.
    • Rankin EC, Isenberg DA (1997). IgA deficiency and SLE: prevalence in a clinic population and a review of the literature. LUPUS, 6(4), 390 - 394.
    • Isenberg D, Rahman MA, Ravirajan CT, Kalsi JK (1997). Anti-DNA antibodies: from gene usage to crystal structures. Immunology Today, 18(4), 149 - 153.

    1996

    • Jeddi PA, Bodman-Smith KB, Lund T, Lydyard PM, Mengle-Gaw L, Isenberg DA, Youinou P, Delves PJ (1996). Agalactosyl IgG and beta1,4-galactosyltransferase gene expression in rheumatoid arthritis patients and in the arthritis-prone MRL lpr/lpr mouse.. Immunology, 87, 654 - 659.
    • Rahman A, Menon S, Latchman DS, Isenberg DA (1996). Sequences of monoclonal antiphospholipid antibodies: variations on an anti-DNA antibody theme. Seminars in Arthritis and Rheumatism, 26, 515 - 525.
    • Kalsi JK, Martin ACR, Hirabayashi Y, Ehrenstein M, Longhurst CM, Ravirajan C, Zvelebil M, Stollar D, Thornton JM, Isenberg DA (1996). Functional and modelling studies of the binding of Human monoclonal anti-DNA antibodies to DNA.. Molecular Immunology, 33, 471 - 483.
    • Rahman MAA, Isenberg DA (1996). Glycosylation of IgG in Rheumatic Diseases. In Isenberg DA, Rademacher TW (Ed.), Abnormalities of IgG Glycosylation and Immunological Disorders (pp. 101 - 118). : John Wiley and Sons.
    • Delves PJ, Kidd VJ (1996). The genetic control of glycosylation.. In Isenberg DA, Rademacher T (Ed.), Abnormalities of IgG Glycosylation and Immunological Disorders (pp. 171 - 199). : John Wiley and Sons Ltd..

    1995

    • Kalsi JK, Martin ACR, Isenberg DA (1995). Structure-function relation of anti-DNA antibodies. Lupus, 4, 245 - 248.
    • Keusch J, Lydyard PM, Isenberg DA, Delves PJ (1995). Beta-1,4-galactosyltransferase activity in B-cells detected using a simple ELISA-based assay.. Glycobiology, 5, 365 - 370.

    1994

    • Rahman MAA, Isenberg DA (1994). Autoantibodies in systemic lupus erythematosus. Current Opinion in Rheumatology, 6, 468 - 473.
    • Keusch J, Bodman KB, Lydyard PM, Isenberg DA, Delves PJ (1994). Lymphocytic galactosyltransferase activities using an ELISA based assay..
    • Jeddi PA, Lund T, Bodman KB, Lydyard PM, Isenberg DA, Delves PJ (1994). Measurement of lymphocytic galactosyltransferase mRNA levels in rheumatoid arthritis patients using an RNAse protection assay..
    • Keusch J, Lydyard PM, Isenberg DA, Delves PJ (1994). Measurement of lymphocytic beta1,4 galactosyltransferase activities in the presence of a neoglycoprotein..
    • Jeddi PA, Bodman KB, Keusch J, Lund T, Lydyard PM, Isenberg DA, Delves PJ (1994). beta1,4-galactosyltransferase gene expression in rheumatoid arthritis..

    1993

    • Edwards JCW, Wilkinson LS, Speight PM, Isenberg DA (1993). Vascular cell adhesion molecule 1 and α4 and β1 integrins in lymphocyte aggregates in Sjögren's syndrome and rheumatoid arthritis. Annals of the Rheumatic Diseases, 52(11), 806 - 811.

    1992

    • Blanco F, Kalsi J, Ravirajan CT, Speight PM, Bradwell AR, Isenberg DA (1992). IgG subclasses in systemic lupus erythematosus and other autoimmune rheumatic diseases. Lupus, 1(6), 391 - 399.

    1991

    • Turner-Stokes L, Jones D, Patterson KG, Todd-Pokropek A, Isenberg DA, Goldstone AH (1991). Measurement of haematological indices of chronic rheumatic disease with two newer generation automated systems, the H1 and H6000 (Technicon).. Annals of the Rheumatic Diseases, 50(8), 583 - 587.

    1990

    • Roitt IM, Dwek RA, Parekh RB, Rademacher TW, Warren C, Alavi A, Axford JS, Bodman K, Bond A, Colaco B, Cooke A, Delves PJ, Hay FC, Isenberg DA, Lydyard PM, MacKenzie L, Rook G, Smith M, Sumar N, Tsoulfa G1990 (1990). The significance of changes in IgG carbohydrate in rheumatoid arthritis and tuberculosis.. Advances in Host Defence Mechanisms, 7, 77 - 91.

    1988

    • Axford JS, Delves PJ, Alavi A, Kidd V, Lund T, Lydyard PM, Isenberg DA, Roitt IM (1988). Reduced lymphocytic galactosyltransferase activity in rheumatoid arthritis is not the result of enzyme inhibition nor gross structural changes in the gene..
    • Isenberg DA, Dudeney C, Williams W, Todd-Pokropek A, Stollar BD (1988). Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleotides.. Annals of the Rheumatic Diseases, 47(9), 717 - 724.

    1987

    • Isenberg DA, Dudeney C, Williams W, Addison I, Charles S, Clarke J, Todd-Pokropek A (1987). Measurement of anti-DNA antibodies: a reappraisal using five different methods.. Annals of the Rheumatic Diseases, 46(6), 448 - 456.

    • Yee CS, Isenberg DA, Prabu A, Sokoll K, Teh L-S, Rahman A, et A (). BILAG 2004 index captures SLE disease activity better than SLEDAI 2000. Annals of the Rheumatic Diseases, , - .
    • Rahman A, Isenberg DA (). Systemic lupus erythematosus and related disorders. In Firth JD, Cox TM, Benz EJ, Warrell DA (Ed.), Oxford Textbook of Medicine (pp. - ). : Oxford University Press.
    • Ripley BJ, Fujimoto M, Serada S, Ohkawara T, Nishikawa T, Terabe F, Matsukawam Y, Stephanou A, Knight RA, Isenberg DA, Latchman D, S K, T N, T (). Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression.. International Immunology, , - . doi:10.1093/intimm/dxq015
    • Rahman A, Isenberg DA (). Systemic lupus erythematosus. New England Journal of Medicine, , - .
    • Bernatsky S, Boivin JF, Joseph L, Gordon C U, M G, D G, E F, P B, S C B, S I, D R, A EA (). The relationship between cancer and medication exposures in systemic lupus erythematosus: a case control study. Annals of the Rheumatic Diseases, , - .